1-5 of 5
Alberto A. Chiappori
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Alberto A. Chiappori, Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, Ram Thapa, Margaret L. Barlow, Zhihua Chen, Dung Tsa Chen, Amer A. Beg, Theresa A. Boyle, Julio Castro, Liza Morgan, Erick Morris, Mehreteab Aregay, Felipe K. Hurtado, Luigi Manenti, Scott Antonia
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (11): 2313–2320.
https://doi.org/10.1158/1078-0432.CCR-21-2742
Published: 01 June 2022
View article titled, Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer
Open the PDF for Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer

Alberto A. Chiappori, Eric Haura, Francisco A. Rodriguez, David Boulware, Rachna Kapoor, Anthony M. Neuger, Richard Lush, Barbara Padilla, Michelle Burton, Charles Williams, George Simon, Scott Antonia, Daniel M. Sullivan, Gerold Bepler
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (5): 1464–1469.
https://doi.org/10.1158/1078-0432.CCR-07-1508
Published: 03 March 2008
View article titled, Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer
Open the PDF for Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer in another window
Journal Articles

Phase I Trial of Poly-l-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies

Jade Homsi, George R. Simon, Chris R. Garrett, Gregory Springett, Ronald De Conti, Alberto A. Chiappori, Pamela N. Munster, Michelle K. Burton, Scott Stromatt, Claudia Allievi, Patrizia Angiuli, Amy Eisenfeld, Daniel M. Sullivan, Adil I. Daud
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19): 5855–5861.
https://doi.org/10.1158/1078-0432.CCR-06-2821
Published: 01 October 2007
View article titled, Phase I Trial of Poly-<sc>l</sc>-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies
Open the PDF for Phase I Trial of Poly-<sc>l</sc>-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies in another window
Journal Articles

A Phase I Pharmacokinetic and Pharmacodynamic Study of S-3304, a Novel Matrix Metalloproteinase Inhibitor, in Patients with Advanced and Refractory Solid Tumors

Alberto A. Chiappori, S. Gail Eckhardt, Ronald Bukowski, Daniel M. Sullivan, Minoru Ikeda, Yoshitaka Yano, Takuko Yamada-Sawada, Yoshikaze Kambayashi, Kazushige Tanaka, Milind M. Javle, Tarek Mekhail, Cindy L. O'Bryant, Patrick J. Creaven
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (7): 2091–2099.
https://doi.org/10.1158/1078-0432.CCR-06-1586
Published: 02 April 2007
View article titled, A Phase I Pharmacokinetic and Pharmacodynamic Study of S-3304, a Novel Matrix Metalloproteinase Inhibitor, in Patients with Advanced and Refractory Solid Tumors
Open the PDF for A Phase I Pharmacokinetic and Pharmacodynamic Study of S-3304, a Novel Matrix Metalloproteinase Inhibitor, in Patients with Advanced and Refractory Solid Tumors in another window
Journal Articles

Phase I Study of the Taxane BMS-188797 in Combination with Carboplatin Administered Every 3 Weeks in Patients with Solid Malignancies

Mayer N. Fishman, Christopher R. Garrett, George R. Simon, Alberto A. Chiappori, Richard M. Lush, William R. Dinwoodie, J. Joseph Mahany, Anne M. Dellaportas, Alan Cantor, Ashwin Gollerki, Marvin B. Cohen, Daniel M. Sullivan
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (2): 523–528.
https://doi.org/10.1158/1078-0432.CCR-05-0928
Published: 20 January 2006
View article titled, Phase I Study of the Taxane BMS-188797 in Combination with Carboplatin Administered Every 3 Weeks in Patients with Solid Malignancies
Open the PDF for Phase I Study of the Taxane BMS-188797 in Combination with Carboplatin Administered Every 3 Weeks in Patients with Solid Malignancies in another window